Oct 26 (Reuters) - Vera Therapeutics Inc :
* VERA THERAPEUTICS ANNOUNCES 96-WEEK EGFR STABILIZATION IN ORIGIN PHASE 2B STUDY OF ATACICEPT IN IGAN IN A LATE-BREAKING ORAL PRESENTATION AT THE AMERICAN SOCIETY OF NEPHROLOGY KIDNEY WEEK 2024
* VERA THERAPEUTICS INC - PIVOTAL ORIGIN 3 TRIAL ON TRACK TO ANNOUNCE TOPLINE RESULTS IN Q2 2025, WITH PLANNED BLA SUBMISSION TO U.S. FDA LATER IN YEAR
* VERA THERAPEUTICS INC - TRIAL MET PRIMARY AND SECONDARY ENDPOINTS WITH SIGNIFICANT PROTEINURIA REDUCTIONS
Source text: Further company coverage:
((Reuters.Briefs@thomsonreuters.com;;))
免责声明:投资有风险,本文并非投资建议,以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请,作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考,不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证,投资者应自行研究并在投资前寻求专业建议。